Few problems occupy the minds of European policy and lawmakers as much as the impending Brexit. With developments moving fast and insecurity rising, national parliaments are taking on an increasingly assertive role. The Europa Institute therefore organised a Leiden Law Exchange on Brexit, parliaments…

Last week, Dr. Larik’s article entitled

In this working paper, Dr. Joris Larik provides an analysis of the governance and dispute settlement mechanisms under the Ireland/Northern Ireland Protocol.

Statement from the Editorial Board of the Common Market Law Review regarding the UK Brexit referendum campaign:

On 27 February 2018, Christa Tobler attended a hearing on the subject of Brexit and dispute settlement at the invitation of the House of Lords, EU Committee, Subcommittee Justice.

After the Brexit referendum in the United Kingdom, Switzerland is worried about what this will mean for its relationship with the European Union.

On 17 October, Armin Cuyvers, associate professor of EU law at Leiden Law School, was a studio guest on the Radio 1 show ‘Een Vandaag’.

For ‘Voor de Ommekeer-TV’, an online television network created by leading Dutch journalists and thinkers to stimulate in-depth journalism and debate, Armin Cuyvers was the studio guest of journalist Paul van Liempt for an hour-long interview on the EU and the many challenges it faces, including Brexit,…

Moritz Jesse, Associate Professor of European Law at the Europa Institute, presented at the annual conference of the Global Legal Network, which took place in November in Tallin (Estonia).

From 28 October to 2 November, Armin Cuyvers was invited by the University of Nagasaki to lecture on EU integration and Brexit.

'Never underestimate universities as a connecting force.' These were the words of Rector Magnificus Carel Stolker in his address on the Dies Natalis, in reference to the imminent Brexit. A message that struck a chord with the Dutch and international media.

We already know a lot about genetics and the risk of breast cancer. But much still needs to be done in breast cancer genetics to improve the prognosis and make sure women at high risk aren’t missed. This is what Professor by Special Appointment Marjanka Schmidt will say in her inaugural lecture on 4…

Researchers from Leiden University Medical Center (LUMC) and Netherlands Cancer Institute (NKI) have discovered how specialised immune cells can detect and remove cancers that are ‘invisible’ to the conventional defence mechanisms of the immune system. Their work has been published in Nature. The findings…

Leiden biophysicist Stefano Coppola has received the prestigious AXA Research Fund postdoctoral fellowship. With this grant he can work for two years on a project to research the role of mechanical factors in the development of pancreatic cancer.

British television channels transmitted in Europe are facing an unpleasant surprise: in the event of a hard Brexit their licences will have to be sorted out correctly, otherwise TV screens may be going black.

In his blog, Armin suggests two legal tools that may jointly help avoid a hard Brexit: delayed exit and decreasing membership.

On 13 February 2018, the European Law Expertise Centre (ECER) and the newly established Centre for International Law (CIR) jointly organised a Brexit conference on the practical implications of international and European law of the Brexit for the interpretation and application of the law in practice…

On 6 and 7 December, the Centre for the Law of EU External Relations (CLEER), which is hosted by the T.M.C. Asser Institute, celebrated its 10th anniversary with a conference on

On 15 November 2019, Dr. Joris Larik, Assistant Professor at LUC and Convener of the International Justice major, convened a policy roundtable on “Brexit’s Next Chapter: The Revised Deal and Global Britain” .

On 1 March Armin Cuvyers was interviewed on BNR national radio on Brexit, the Draft Withdrawal Agreement of the Commission and the key Brexit speech by Theresa May planned for 2 March.

Leiden PhD student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with light. Zhou’s new compound does this extra efficiently by cleverly self-organising into nanoparticles.…

On 5 April 2017, Prof. Christa Tobler gave a guest lecture at the Centre for European Studies of the O.P Jindal Global University in Delhi on the topic of „“Brexit“ - what is it about and what could it mean for India?“

On 11 December Armin Cuyvers, Associate Professor European Law at the Europa Institute of Leiden Law School, was a studio guest on the news programme EenVandaag to talk about the possible scenarios for Brexit.

Joris Larik, Assistant Professor of Comparative, EU and International Law at LUC The Hague and Convener of the International Justice major, presented his research at the Midyear Meeting of the American Society of International Law, which was hosted by Brooklyn Law School in New York City.

Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…

The contribution ‘Article 50 TEU and Brexit: the legal contours of a political drama’ is the most read article of the Dutch Journal for EU Law (NtER).

In the BNR lobby panel, a topic is highlighted every week that lies at the intersection of entrepreneurship and politics. Arco Timmermans, Professor by Special Appointment of Public Affairs, talks about the effect of Brexit on lobbying in the EU.

Switzerland and the EU are conducting negotiations on a renewed institutional framework for a number of already existing and future market access agreements.

Leiden University Medical Center (LUMC) has spent the past five years coordinating an international study of genetic mutations and breast cancer risks. The results will make it easier to determine which genes increase the risk of breast cancer and to what extent. The researchers published their results…

PhD defence

Ariane Briegel wants to use bacteria to detect cancer at an early stage. Together with postdoc Alise Muok, she is developing a method to quickly and cheaply test the urine of patients for the presence of suspicious molecules. They receive a grant of approximately 150,000 euros from the Dutch Cancer…

Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer.

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

The British people have voted in favour of Brexit: the United Kingdom will leave the European Union. How will this vote be transformed into a legal and political reality?

The United Kingdom’s relationship with the European Union was supposed to be definitively settled several times during the past decade – yet it was not. The 2016 referendum brought about a surge in interest in legal questions, especially of EU law and international economic law. This presented scholars…

With a Vici grant of 1.5 million euros, Professor of Mathematical biology Roeland Merks will look for ways to fix messy and leaky blood vessels in tumours. His research combines mathematical simulations and lab experiments in a unique way.

On Saturday 25 June 2016, the Europa Institute hosted the 55th Leiden-London Meeting, with the overall title:

On Tuesday 24 April 2018, Nick Clegg, who served as Deputy Prime Minister of the United Kingdom, gave a guestlecture to first year students public administration about the profound dilemmas on Brexit. The lecture was part of a political science course within the Bachelor Public Administration of Leiden…

Modified viruses can both kill cancer cells and activate the immune system. This is what an LUMC team discovered while researching a new prostate cancer therapy.

A therapeutic vaccine against HPV-16 (type 16 human papillomavirus) improves the survival rate in cervical cancer patients. A new study by ISA Pharmaceuticals B.V. (a Leiden-based biotechnology company) and the Leiden University Medical Center (LUMC) shows that this vaccine produces a more robust response…

Chemist Gerjan de Bruin has designed a method of slowing down the degradation process of proteins in cells. This may contribute to new cancer medicines with fewer side-effects. PhD defence on 1 June.

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

The shocking murder of MP Jo Cox has brought it home to the British public that the referendum debate is in disarray. How has the campaign been handled and what would be the consequences of a Brexit? Jan Rood, Professor by special appointment of European Integration, and political scientist Hans Vollaard…

The research within the Division of Cell Systems and Drug Safety, headed by Prof. Bob van de Water, is focused on novel therapeutic modalities and novel concepts in early drug discovery, in order to develop more effective and safer therapeutic strategies. We generate advanced cell and computational…

We have followed the UK referendum of Thursday, 23 June 2016, with great interest and indeed concern.

Leiden chemists, together with colleagues at the University of York (UK) and Technion (Israel) have discovered a small, sugar-like molecule that maintains the integrity of tissue around a tumour during cancer. This molecule prevents tumour cells from spreading from the primary cancer site to colonise…

Cell biologist Erik Danen has been awarderd a grant of half a million euros to study how tumor cells spread throughout the body en develop drug resistance. This was announced mid-August by the Dutch Cancer Society Fund (KWF).

Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.